eligibility_summary
Adults 18–75 with MM or primary plasma cell leukemia after ≥3 prior lines incl PI, IMiD, anti‑CD38 (or refractory), progressing on/within 12 mo of last therapy (CAR‑T exempt), with measurable disease, ECOG 0–1, life ≥12 wks, adequate marrow/liver/renal/coagulation, SaO2>91%, LVEF≥50%, contraception/consent. Exclude GVHD/immunosuppression, allo‑HSCT or ≥2 autos/auto <12 wks, recent therapies/investigational, chronic steroids, major surgery, uncontrolled HTN/CV/systemic disease, CNS MM, active infections/viral serology, pregnancy, other malignancy, organ transplant, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: RD140 injection—an autologous, fully human dual‑target CAR‑T cell therapy (biologic) that recognizes BCMA and GPRC5D, given as a single infusion at 1–6×10^5 CAR‑T cells/kg. Mechanism of action: Patient T cells are engineered to express chimeric antigen receptors that bind BCMA and GPRC5D on malignant plasma cells, binding triggers CAR signaling, activating T‑cell cytotoxicity and cytokine release to lyse tumor cells. Cells/pathways targeted: Pathologic plasma cells in relapsed/refractory multiple myeloma or plasma cell leukemia, surface antigens BCMA (TNFRSF17) and GPRC5D, activation of T‑cell effector pathways through CAR signaling to overcome antigen escape via dual targeting.